SCHEMBL16799129

SCHEMBL16799129

C=C(C)C(=O)OCCC[N+](C)(C)CCCS(=O)(=O)[O-]

nearest known ligand 0.47

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
BBOX1 O75936 5/20 0.47
TSHR P16473 3/20 0.45
THRB P10828 1/20 0.39
POLB P06746 2/20 0.36
APEX1 P27695 1/20 0.36
HTT P42858 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
MEN1 O00255 1/20 0.32
LMNA P02545 1/20 0.32
GRK2 P25098 1/20 0.32
KMT2A Q03164 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
CHRM5 P08912 1/20 0.32
CHRM1 P11229 1/20 0.32
CHRM3 P20309 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16799116 0.96 TSHR (0.47) BBOX1TSHRTHRBPOLBAPEX1
SCHEMBL16798910 0.94 TSHR (0.50) BBOX1TSHRTHRBPOLBAPEX1
SCHEMBL18151499 0.94 TSHR (0.50) BBOX1TSHRTHRBPOLBAPEX1
SCHEMBL16799119 0.94 TSHR (0.46) BBOX1TSHRTHRBPOLBAPEX1
SCHEMBL1547906 0.94 TSHR (0.50) BBOX1TSHRTHRBPOLBAPEX1
SCHEMBL16799121 0.94 TSHR (0.50) BBOX1TSHRTHRBPOLBAPEX1
SCHEMBL18151862 0.94 TSHR (0.46) BBOX1TSHRTHRBPOLBAPEX1
SCHEMBL16799360 0.94 TSHR (0.50) BBOX1TSHRTHRBPOLBAPEX1
SCHEMBL16799567 0.94 TSHR (0.46) BBOX1TSHRTHRBPOLBAPEX1
SCHEMBL16799049 0.94 TSHR (0.46) BBOX1TSHRTHRBPOLBAPEX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4165465-B1 SYSTEMS AND METHODS FOR INDICATING THE TIME ELAPSED SINCE THE OCCURRENCE OF A TRIGGERING EVENT JOHNSON & JOHNSON VISION CARE (US) 2026-02-18 EP disclosed
US-12509583-B2 Particle surface modification to increase compatibility and stability in hydrogels JOHNSON & JOHNSON VISION CARE, INC. (US) 2025-12-30 US disclosed
US-20250161025-A1 COMPOSITIONS, DEVICES, AND METHODS FOR PREVENTING POSTERIOR CAPSULE OPACIFICATION (PCO) OHIO STATE INNOVATION FOUNDATION 2025-05-22 US disclosed
EP-4515302-A1 LIGHT-FILTERING MATERIALS FOR BIOMATERIAL INTEGRATION AND METHODS THEREOF Johnson & Johnson Vision Care, Inc. (US) 2025-03-05 EP disclosed
EP-4515301-A1 SHAPE ENGINEERING OF PARTICLES TO CREATE A NARROW SPECTRAL FILTER AGAINST A SPECIFIC PORTION OF THE LIGHT SPECTRUM Johnson & Johnson Vision Care, Inc. (US) 2025-03-05 EP disclosed
EP-4515307-A1 THERMALLY STABLE NANOPARTICLES AND METHODS OF MAKING THEM Johnson & Johnson Vision Care, Inc. (US) 2025-03-05 EP disclosed
EP-4515304-A1 PARTICLE SURFACE MODIFICATION TO INCREASE COMPATIBILITY AND STABILITY IN HYDROGELS Johnson & Johnson Vision Care, Inc. (US) 2025-03-05 EP disclosed
EP-4515303-A1 USING PARTICLES FOR LIGHT FILTERING Johnson & Johnson Vision Care, Inc. (US) 2025-03-05 EP disclosed
CN-118055935-A Anthraquinone-functionalized polymerization initiators and their use in the manufacture of ophthalmic lenses 强生视力健公司 2024-05-17 CN disclosed
CN-113874780-B Multifocal contact lenses exhibiting improved vision properties 强生视力健公司 2024-05-14 CN disclosed
EP-3077476-B1 NANOCRYSTALS COMPLEXED WITH FUNCTIONALIZABLE ENHANCED AFFINITY LIGANDS AND USE THEREOF NEXDOT (FR) 2020-02-12 EP disclosed
US-10465030-B2 Nanoparticles complexed with functionalizable enhanced affinity ligands and use thereof NEXDOT (FR) 2019-11-05 US disclosed
US-20190161563-A1 PROTEIN AGGREGATION INHIBITOR OSAKA ORGANIC CHEMICAL INDUSTRY LTD. (JP) 2019-05-30 US disclosed
US-20190002459-A1 HYDROXYPHENYL PHENANTHROLINES AS POLYMERIZABLE BLOCKERS OF HIGH ENERGY LIGHT JOHNSON & JOHNSON VISION CARE, INC. 2019-01-03 US disclosed
US-20190002415-A1 HYDROXYPHENYL NAPHTHOTRIAZOLES AS POLYMERIZABLE BLOCKERS OF HIGH ENERGY LIGHT JOHNSON & JOHNSON VISION CARE, INC. 2019-01-03 US disclosed
US-20180118859-A1 PROTEIN AGGREGATION INHIBITOR OSAKA ORGANIC CHEMICAL INDUSTRY LTD. (JP) 2018-05-03 US disclosed
EP-3296314-A1 PROTEIN AGGREGATION INHIBITOR Osaka Organic Chemical Industry Ltd. (JP) 2018-03-21 EP disclosed
US-20160304648-A1 NANOPARTICLES COMPLEXED WITH FUNCTIONALIZABLE ENHANCED AFFINITY LIGANDS AND USE THEREOF NEXDOT (FR) 2016-10-20 US disclosed
EP-3077476-A1 NANOPARTICLES COMPLEXED WITH FUNCTIONALIZABLE ENHANCED AFFINITY LIGANDS AND USE THEREOF Nexdot (FR) 2016-10-12 EP disclosed
WO-2015082656-A1 NANOPARTICLES COMPLEXED WITH FUNCTIONALIZABLE ENHANCED AFFINITY LIGANDS AND USE THEREOF NEXDOT (FR) 2015-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12509583-B2 Particle surface modification to increase compatibility and stability in hydrogels MYH10, MYOC, UACA BBOX1 2704/4885TSHR 910/4885THRB 3011/4885
US-20190002459-A1 HYDROXYPHENYL PHENANTHROLINES AS POLYMERIZABLE BLOCKERS OF HIGH ENERGY LIGHT HRH2, HRH3, HRH1 BBOX1 1000/4885TSHR 3007/4885THRB 2569/4885
US-20190002415-A1 HYDROXYPHENYL NAPHTHOTRIAZOLES AS POLYMERIZABLE BLOCKERS OF HIGH ENERGY LIGHT HRH3, HMGB3, CRYAB BBOX1 2143/4885TSHR 2809/4885THRB 3242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.